Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Hepatobiliary/Pancreas

Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma

Cancer Discovery | Oct 09, 2019 Hepatobiliary/Pancreas

Differences in pathology, staging, and treatment between HIV+ and uninfected patients with microscopically confirmed hepatocellular carcinoma

Cancer Epidemiology, Biomarkers & Prevention | Oct 09, 2019 Hepatobiliary/Pancreas

First-in-human phase I study of fisogatinib (BLU-554) validates aberrant fibroblast growth factor 19 signaling as a driver event in hepatocellular carcinoma

Cancer Discovery | Oct 09, 2019 Hepatobiliary/Pancreas

Prediagnostic leukocyte telomere length and pancreatic cancer survival

Cancer Epidemiology, Biomarkers & Prevention | Oct 07, 2019 Hepatobiliary/Pancreas

Herbal medicine containing aristolochic acid and the risk of primary liver cancer in patients with hepatitis C virus infection

Cancer Epidemiology, Biomarkers & Prevention | Oct 07, 2019 Hepatobiliary/Pancreas

Combination of ALBI and APRI to predict posthepatectomy liver failure after liver resection for HBV-related HCC patients

Cancer Management and Research | Oct 07, 2019 Hepatobiliary/Pancreas

Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores

Gastroenterology | Oct 03, 2019 Hepatobiliary/Pancreas

RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas

Modern Pathology | Oct 03, 2019 Hepatobiliary/Pancreas

MAGEC2 correlates with unfavorable prognosis and promotes tumor development in HCC via epithelial-mesenchymal transition

OncoTargets and Therapy | Oct 01, 2019 Hepatobiliary/Pancreas

Comparing treatment patterns of hepatocellular carcinoma at academic centers and non-academic centers within the mountain region

American Journal of Surgery | Sep 30, 2019 Hepatobiliary/Pancreas

« Prev 1 … 41 42 43 44 45 … 118 Next »

Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma

Differences in pathology, staging, and treatment between HIV+ and uninfected patients with microscopically confirmed hepatocellular carcinoma

First-in-human phase I study of fisogatinib (BLU-554) validates aberrant fibroblast growth factor 19 signaling as a driver event in hepatocellular carcinoma

Prediagnostic leukocyte telomere length and pancreatic cancer survival

Herbal medicine containing aristolochic acid and the risk of primary liver cancer in patients with hepatitis C virus infection

Combination of ALBI and APRI to predict posthepatectomy liver failure after liver resection for HBV-related HCC patients

Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores

RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas

MAGEC2 correlates with unfavorable prognosis and promotes tumor development in HCC via epithelial-mesenchymal transition

Comparing treatment patterns of hepatocellular carcinoma at academic centers and non-academic centers within the mountain region

MD Clip on Recent Advances in Lipid Management with Dr Gopinath

Article: Anti-Inflammatory Diets for Pain and Arthritis Management

Many young adults have high long-term risk for cardiovascular disease, study finds

Article on Hypertension in CKD Patients: Management Updates

New research aims to transform treatments of aggressive blood cancer

Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma

Differences in pathology, staging, and treatment between HIV+ and uninfected patients with microscopically confirmed hepatocellular carcinoma

First-in-human phase I study of fisogatinib (BLU-554) validates aberrant fibroblast growth factor 19 signaling as a driver event in hepatocellular carcinoma

Prediagnostic leukocyte telomere length and pancreatic cancer survival

Herbal medicine containing aristolochic acid and the risk of primary liver cancer in patients with hepatitis C virus infection

Combination of ALBI and APRI to predict posthepatectomy liver failure after liver resection for HBV-related HCC patients

Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores

RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas

MAGEC2 correlates with unfavorable prognosis and promotes tumor development in HCC via epithelial-mesenchymal transition

Comparing treatment patterns of hepatocellular carcinoma at academic centers and non-academic centers within the mountain region

MD Clip on Recent Advances in Lipid Management with Dr Gopinath

Article: Anti-Inflammatory Diets for Pain and Arthritis Management

Many young adults have high long-term risk for cardiovascular disease, study finds

Article on Hypertension in CKD Patients: Management Updates

New research aims to transform treatments of aggressive blood cancer

Select Specialty

Select Topic